Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPL | P40238 | 6/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44739 | 0.85 | MPL (1.00) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL30122901 | 0.85 | MPL (1.00) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL474342 | 0.84 | MPL (0.61) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL1801817 | 0.83 | MPL (0.63) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL3763291 | 0.82 | MPL (0.50) | MPLHSD17B10MAPTALDH1A1RAB9A | |
| SCHEMBL13002992 | 0.81 | MPL (0.49) | MPLMAPTKDM4EALDH1A1RAB9A | |
| SCHEMBL15417599 | 0.80 | MPL (0.60) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL474161 | 0.80 | MPL (1.00) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL1800719 | 0.79 | MPL (0.65) | MPLHSD17B10MAPTMEN1KMT2A | |
| SCHEMBL4868729 | 0.79 | MPL (0.58) | MPLHSD17B10MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109293652-B | Substituted thiazole derivative and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474758-B2 | Thienopyrimidinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2016-10-25 | — | — | US | disclosed |
| CN-103755720-B | Thienopyrimidine derovatives as TRPA1 regulator | 格兰马克药品股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-7951814-B2 | Quinazolinedione derivatives as TRPA1 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2011-05-31 | — | — | US | disclosed |
| WO-2010125469-A1 | PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125469-A1 | PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010109329-A1 | FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109334-A2 | THIENOPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004390-A1 | QUINAZOLINE DIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MPL 286/4885HSD17B10 2489/4885MAPT 519/4885 |
| US-20090325987-A1 | QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPC3 | MPL 4421/4885HSD17B10 2398/4885MAPT 1842/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | MPL 286/4885HSD17B10 2489/4885MAPT 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.